Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.68 |
| ▸ | F2 | P00734 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MGAM | O43451 | 2/20 | 0.49 |
| ▸ | SI | P14410 | 2/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462351 | 1.00 | F10 (0.68) | F10F2CYP1A2F3MAPT | |
| Diethylamine SCHEMBL9564282 | 0.87 | F2 (0.56) | F10F2CYP1A2F3MAPT | |
| SCHEMBL14012043 | 0.81 | MAPT (0.69) | F10F2CYP1A2F3MAPT | |
| SCHEMBL31295514 | 0.81 | CYP1A2 (0.62) | F10F2CYP1A2F3MAPT | |
| SCHEMBL16807421 | 0.81 | MAPT (0.69) | F10F2CYP1A2F3MAPT | |
| SCHEMBL6805427 | 0.81 | ALDH1A1 (0.57) | F10F2CYP1A2MAPTGAA | |
| SCHEMBL6805432 | 0.81 | ALDH1A1 (0.57) | F10F2CYP1A2MAPTGAA | |
| SCHEMBL3438182 | 0.79 | ALDH1A1 (0.54) | F10F2CYP1A2F3MAPT | |
| SCHEMBL3438181 | 0.79 | ALDH1A1 (0.54) | F10F2CYP1A2F3MAPT | |
| SCHEMBL3438525 | 0.78 | ALDH1A1 (0.53) | F10F2CYP1A2F3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | KIAKOS KONSTANTINOS (AT) | 2020-12-24 | — | — | US | disclosed |
| WO-2019097080-A9 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | KIAKOS KONSTANTINOS (AT) | 2020-10-15 | — | — | WO | disclosed |
| EP-3713916-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | Kiakos, Konstantinos (AT) | 2020-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | STAT3, JAK2, STAT6 | F10 4246/4885F2 4376/4885CYP1A2 4544/4885 |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | STAT3, JAK2, STAT6 | F10 4246/4885F2 4376/4885CYP1A2 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.